MDGL EBITDA | MADRIGAL PHARMACEUTICALS, INC.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) EBITDA

2026-06-30: Basis Reported; EBITDA -$55.93M*; Operating income -$56.31M; Depreciation and amortization $381.00K*.
2026-03-31: Basis Reported; EBITDA -$92.34M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$59.22M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$113.62M*; Operating income -$113.97M; Depreciation and amortization $358.00K*.

Complete source-backed ebitda history.

Available history: 2009-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$55.93M*	-$56.31M	$381.00K*	$364.25M	-15.35%*	$4.25M*	$23.33M*	(m)	(m)	$289.38M	(m)
2026-03-31	Reported	-$92.34M	(m)	(m)	(m)	-29.66%	$3.85M	-$167.44M	(m)	(m)	$268.52M	(m)
2025-12-31	Reported	-$59.22M	(m)	(m)	(m)	-18.44%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$113.62M*	-$113.97M	$358.00K*	$287.27M	-39.55%*	$857.00K*	$79.85M*	(m)	(m)	$209.12M	(m)
2025-06-30	Reported	-$46.83M*	-$47.20M	$377.00K*	$212.80M	-22.00%*	$0.00*	-$47.05M*	(m)	(m)	$196.86M	(m)
2025-03-31	Reported	-$78.93M	(m)	(m)	(m)	-57.51%	$0.00	-$88.89M	$4.51M	(m)	$167.88M	(m)
2024-12-31	Reported	-$66.63M	(m)	(m)	(m)	-64.49%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$116.01M*	-$116.30M	$298.00K*	$62.17M	-186.58%*	$779.00K*	-$66.98M*	(m)	(m)	$107.58M	(m)
2024-06-30	Reported	-$162.27M*	-$162.54M	$267.00K*	$14.64M	-1108.55%*	$131.00K*	-$134.94M*	(m)	(m)	$105.45M	(m)
2024-03-31	Reported	-$151.87M	(m)	(m)	(m)	(m)	$357.00K	-$149.16M	$0.00	(m)	$80.80M	(m)
2023-12-31	Reported	-$117.03M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$98.40M*	-$98.53M	$135.00K*	$0.00	(m)	$339.00K*	-$84.92M*	(m)	(m)	$27.58M	(m)
2023-06-30	Reported	-$86.32M*	-$86.45M	$126.00K*	$0.00	(m)	$69.00K*	-$75.31M*	(m)	(m)	$17.84M	(m)
2023-03-31	Reported	-$78.21M	(m)	(m)	(m)	(m)	$35.00K	-$84.07M	(m)	(m)	$16.18M	(m)
2022-12-31	Reported	-$85.17M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$80.29M*	-$80.41M	$121.00K*	(m)	(m)	$33.00K*	-$59.07M*	(m)	(m)	(m)	(m)
2022-06-30	Reported	-$70.16M*	-$70.27M	$110.00K*	(m)	(m)	$103.00K*	-$57.36M*	(m)	(m)	(m)	(m)
2022-03-31	Reported	-$57.48M	(m)	(m)	(m)	(m)	$52.00K	-$49.91M	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$64.5M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$63.06M*	-$63.16M	$97.00K*	(m)	(m)	$50.00K*	-$45.56M*	(m)	(m)	(m)	(m)
2021-06-30	Reported	-$61.65M*	-$61.74M	$89.00K*	(m)	(m)	$2.00K*	-$46.88M*	(m)	(m)	(m)	(m)
2021-03-31	Reported	-$52.87M	(m)	(m)	(m)	(m)	$44.00K	-$43.43M	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$59.44M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$58.67M*	-$58.79M	$115.00K*	(m)	(m)	$3.00K*	-$47.85M*	(m)	(m)	(m)	(m)
2020-06-30	Reported	-$50.21M*	-$50.33M	$115.00K*	(m)	(m)	$7.00K*	-$24.26M*	(m)	(m)	(m)	(m)
2020-03-31	Reported	-$37.88M	(m)	(m)	(m)	(m)	$314.00K	-$30.51M	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$29.93M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$24.17M*	-$24.20M	$28.00K*	(m)	(m)	-$2.00K*	-$11.32M*	(m)	(m)	(m)	(m)
2019-06-30	Reported	-$22.68M*	-$22.70M	$28.00K*	(m)	(m)	-$1.00K*	-$11.54M*	(m)	(m)	(m)	(m)
2019-03-31	Reported	-$18.09M	(m)	(m)	(m)	(m)	$41.00K	-$6.48M	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$14.43M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$11.31M*	-$11.33M	$24.00K*	(m)	(m)	$13.00K*	-$5.24M*	(m)	(m)	(m)	(m)
2018-06-30	Reported	-$7.80M*	-$7.83M	$24.00K*	(m)	(m)	$0.00*	-$5.36M*	(m)	(m)	(m)	(m)
2018-03-31	Reported	-$7.05M	(m)	(m)	(m)	(m)	$1.00K	-$8.64M	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$8.85M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$8.63M*	-$8.64M	$9.00K*	(m)	(m)	$0.00*	-$4.95M*	(m)	(m)	(m)	(m)
2017-06-30	Reported	(m)	-$8.44M	(m)	(m)	(m)	$123.00K*	-$7.65M*	(m)	(m)	(m)	(m)
2017-03-31	Reported	(m)	-$6.08M	(m)	(m)	(m)	$2.00K	-$3.77M	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$14.09M	(m)	(m)	(m)	(m)	-$9.24M*	(m)	(m)	(m)	(m)
2016-06-30	Reported	-$2.54M*	-$2.64M	$96.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Reported	-$692,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$759,368.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$680,029.00	(m)	(m)	(m)	(m)	$13.00K*	(m)	(m)	(m)	(m)	(m)
2015-06-30	Reported	-$19.4M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Reported	-$20.16M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$19.73M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$19.25M	(m)	(m)	(m)	(m)	$37.00K*	(m)	(m)	(m)	(m)	(m)
2014-06-30	Reported	-$21.6M	(m)	(m)	(m)	(m)	$25.00K*	(m)	(m)	(m)	(m)	(m)
2014-03-31	Reported	-$22.74M	(m)	(m)	(m)	(m)	$23.00K	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	-$23.3M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	-$21.69M	(m)	(m)	(m)	(m)	$16.00K*	(m)	(m)	(m)	(m)	(m)
2013-06-30	Reported	-$21.96M	(m)	(m)	(m)	(m)	$395.00K*	(m)	(m)	(m)	(m)	(m)
2013-03-31	Reported	-$20.16M	(m)	(m)	(m)	(m)	$276.00K	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	-$17.59M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	-$14.34M	(m)	(m)	(m)	(m)	$209.00K*	(m)	(m)	(m)	(m)	(m)
2012-06-30	Reported	-$13.83M	(m)	(m)	(m)	(m)	$65.00K*	(m)	(m)	(m)	(m)	(m)
2012-03-31	Reported	-$14.34M	(m)	(m)	(m)	(m)	$147.00K	(m)	(m)	(m)	(m)	(m)
2011-12-31	Reported	-$9.95M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	-$11.82M	(m)	(m)	(m)	(m)	$263.00K*	(m)	(m)	(m)	(m)	(m)
2011-06-30	Reported	-$11.61M	(m)	(m)	(m)	(m)	$35.00K*	(m)	(m)	(m)	(m)	(m)
2011-03-31	Reported	-$10.53M	(m)	(m)	(m)	(m)	$10.00K	(m)	(m)	(m)	(m)	(m)
2010-12-31	Reported	-$7.9M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2010-09-30	Reported	-$9.76M*	-$10.23M	$473.00K*	(m)	(m)	$70.00K*	(m)	(m)	(m)	(m)	(m)
2010-06-30	Reported	(m)	-$9.04M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$298.59M	(m)	(m)	(m)	-31.16%	$467.00K	-$189.55M	(m)	(m)	$813.83M	$0.00
2024-12-31	Reported	-$496.78M	(m)	(m)	(m)	-275.78%	$1.46M	-$455.57M	$6.23M	(m)	$435.06M	$0.00
2024-09-30	Rolling	(m)	-$548.05M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-06-30	Rolling	(m)	-$530.28M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-03-31	Rolling	(m)	-$454.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-12-31	Reported	-$379.97M	(m)	(m)	(m)	(m)	$1.48M	-$324.23M	$0.00	(m)	$108.15M	$0.00
2023-12-31	Rolling	(m)	-$380.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Rolling	(m)	-$348.62M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-06-30	Rolling	(m)	-$330.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-03-31	Rolling	(m)	-$314.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$293.1M	(m)	(m)	(m)	(m)	$217.00K	-$224.86M	$0.00	(m)	$48.13M	$0.00
2022-12-31	Rolling	(m)	-$293.57M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Rolling	(m)	-$272.87M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-06-30	Rolling	(m)	-$255.62M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-03-31	Rolling	(m)	-$247.09M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$242.08M	(m)	(m)	(m)	(m)	$209.00K	-$183.92M	(m)	(m)	(m)	$0.00
2021-12-31	Rolling	(m)	-$242.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Rolling	(m)	-$237.44M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$233.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$221.65M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$206.2M	(m)	(m)	(m)	(m)	$334.00K	-$157.56M	(m)	(m)	(m)	$0.00
2020-12-31	Rolling	(m)	-$206.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$177.07M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$94.86M	(m)	(m)	(m)	(m)	$172.00K	-$41.62M	(m)	(m)	(m)	$0.00
2019-09-30	Rolling	(m)	-$79.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$66.61M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$51.73M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$40.59M	(m)	(m)	(m)	(m)	$22.00K	-$25.51M	(m)	(m)	(m)	$0.00
2018-12-31	Rolling	(m)	-$40.68M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$35.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$32.44M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$33.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$31.99M	(m)	(m)	(m)	(m)	$125.00K	-$22.32M	(m)	(m)	(m)	(m)
2017-12-31	Rolling	(m)	-$32.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$25.22M	(m)	(m)	(m)	(m)	$3.00K	-$17.61M	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$27.85M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$14.64M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$31.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$2.57M	(m)	(m)	(m)	(m)	$58.00K	(m)	(m)	(m)	(m)	(m)
2015-12-31	Rolling	(m)	-$51.10M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$60.61M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	-$79.18M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	-$81.38M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$83.28M	(m)	(m)	(m)	(m)	$144.00K	(m)	(m)	(m)	(m)	(m)
2014-12-31	Rolling	(m)	-$83.95M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Rolling	(m)	-$87.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	Rolling	(m)	-$89.85M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	Rolling	(m)	-$90.21M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	-$87.04M	(m)	(m)	(m)	(m)	$769.00K	(m)	(m)	(m)	(m)	(m)
2013-12-31	Rolling	(m)	-$87.56M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Rolling	(m)	-$81.82M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-06-30	Rolling	(m)	-$74.56M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	Rolling	(m)	-$66.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	-$60.2M	(m)	(m)	(m)	-40954.42%	$505.00K	(m)	(m)	(m)	(m)	(m)
2012-12-31	Rolling	(m)	-$60.94M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Rolling	(m)	-$53.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-06-30	Rolling	(m)	-$51.16M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-03-31	Rolling	(m)	-$49.03M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-12-31	Reported	-$43.97M	(m)	(m)	(m)	(m)	$690.00K	(m)	(m)	(m)	(m)	(m)
2011-12-31	Rolling	(m)	-$45.43M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2010-12-31	Reported	-$34.97M	(m)	(m)	(m)	(m)	$136.00K	(m)	(m)	(m)	(m)	(m)
2009-12-31	Reported	$81.77M	(m)	(m)	(m)	(m)	$454.00K	(m)	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
BIOMARIN PHARMACEUTICAL INC (BMRN)	United States	$11.879B	151.80
Elanco Animal Health Inc (ELAN)	United States	$11.177B	-61.80
CORCEPT THERAPEUTICS INC (CORT)	United States	$12.804B	169.10
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
Axsome Therapeutics, Inc. (AXSM)	United States	$10.274B	-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)	United States	$9.331B	-42.28
CYTOKINETICS INC (CYTK)	United States	$9.130B	-11.86
Protagonist Therapeutics, Inc (PTGX)	United States	$8.883B	95.52
TG THERAPEUTICS, INC. (TGTX)	United States	$8.805B	19.05